Abbott Laboratories (NYSE:ABT) Shares Sold by Delta Financial Advisors LLC

Delta Financial Advisors LLC lessened its stake in Abbott Laboratories (NYSE:ABT) by 1.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 16,029 shares of the healthcare product maker’s stock after selling 158 shares during the quarter. Delta Financial Advisors LLC’s holdings in Abbott Laboratories were worth $1,764,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Altshuler Shaham Ltd acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $28,000. Cornerstone Planning Group LLC acquired a new stake in shares of Abbott Laboratories in the 2nd quarter valued at about $28,000. FWL Investment Management LLC acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $33,000. True Wealth Design LLC acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $33,000. Finally, Quarry LP raised its stake in Abbott Laboratories by 132.9% during the second quarter. Quarry LP now owns 333 shares of the healthcare product maker’s stock worth $36,000 after acquiring an additional 190 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling

In related news, EVP Andrea F. Wainer sold 42,500 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the completion of the sale, the executive vice president now directly owns 65,027 shares in the company, valued at $7,315,537.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, EVP Andrea F. Wainer sold 42,500 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $112.50, for a total value of $4,781,250.00. Following the completion of the sale, the executive vice president now owns 65,027 shares in the company, valued at approximately $7,315,537.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP John A. Jr. Mccoy sold 472 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $55,932.00. Following the completion of the sale, the vice president now owns 18,760 shares of the company’s stock, valued at approximately $2,223,060. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,435 shares of company stock worth $6,451,298. Corporate insiders own 1.10% of the company’s stock.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock traded down $0.69 on Thursday, hitting $105.21. The company had a trading volume of 2,284,698 shares, compared to its average volume of 5,630,331. The business has a 50-day simple moving average of $114.42 and a 200-day simple moving average of $107.59. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.64 and a quick ratio of 1.16. The company has a market cap of $182.56 billion, a PE ratio of 32.29, a PEG ratio of 2.63 and a beta of 0.74. Abbott Laboratories has a 52 week low of $89.67 and a 52 week high of $121.64.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.02. The business had revenue of $9.96 billion during the quarter, compared to analysts’ expectations of $9.88 billion. Abbott Laboratories had a net margin of 14.27% and a return on equity of 20.65%. The business’s revenue was up 2.2% on a year-over-year basis. During the same period last year, the firm posted $1.03 earnings per share. Research analysts expect that Abbott Laboratories will post 4.62 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.09%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s payout ratio is 67.48%.

Analyst Ratings Changes

ABT has been the topic of several research reports. Citigroup increased their price objective on shares of Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Evercore ISI increased their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Barclays increased their price objective on shares of Abbott Laboratories from $133.00 to $141.00 and gave the stock an “overweight” rating in a research note on Friday, January 26th. Royal Bank of Canada dropped their price objective on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, Raymond James increased their price objective on shares of Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $121.31.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.